NYSE:LLYPharmaceuticals
Eli Lilly (LLY) Stock Still Looks Cheap Following Its 407% Run
Eli Lilly stock has returned roughly 4x over the past five years, yet the current valuation picture is split, with the intrinsic value estimate pointing to meaningful upside while the broader checks suggest the shares are not an obvious bargain.
Eli Lilly has delivered a very large 5 year return of about 406.7%, which puts extra scrutiny on whether recent gains already reflect the key growth drivers.
Expectations around new therapies in obesity, neuroscience and oncology can support...